Filippo de Marinis

1997–2025 年に発表

別表記
Filippo De Marinis
173
論文数
41,088
被引用数
78
h 指数
164
i10 指数

被引用数

Filippo de Marinis の年別被引用数1971 年: 被引用 1 件1993 年: 被引用 2 件1996 年: 被引用 1 件1997 年: 被引用 4 件1998 年: 被引用 2 件1999 年: 被引用 20 件2000 年: 被引用 25 件2001 年: 被引用 14 件2002 年: 被引用 20 件2003 年: 被引用 34 件2004 年: 被引用 27 件2005 年: 被引用 50 件2006 年: 被引用 47 件2007 年: 被引用 52 件2008 年: 被引用 51 件2009 年: 被引用 106 件2010 年: 被引用 129 件2011 年: 被引用 178 件2012 年: 被引用 179 件2013 年: 被引用 245 件2014 年: 被引用 196 件2015 年: 被引用 234 件2016 年: 被引用 230 件2017 年: 被引用 300 件2018 年: 被引用 376 件2019 年: 被引用 1,150 件2020 年: 被引用 1,438 件2021 年: 被引用 1,681 件2022 年: 被引用 1,320 件2023 年: 被引用 1,058 件2024 年: 被引用 1,874 件2025 年: 被引用 1,048 件2026 年: 被引用 36 件1972〜1992 年は被引用が無いため表示していません1994〜1995 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,284 件、この内訳の 20.4%中国: 引用元論文 2,389 件、この内訳の 14.8%イタリア: 引用元論文 1,108 件、この内訳の 6.9%日本: 引用元論文 880 件、この内訳の 5.5%フランス: 引用元論文 788 件、この内訳の 4.9%イギリス: 引用元論文 725 件、この内訳の 4.5%スペイン: 引用元論文 688 件、この内訳の 4.3%ドイツ: 引用元論文 657 件、この内訳の 4.1%カナダ: 引用元論文 515 件、この内訳の 3.2%韓国: 引用元論文 502 件、この内訳の 3.1%スイス: 引用元論文 407 件、この内訳の 2.5%オランダ: 引用元論文 392 件、この内訳の 2.4%
0%20.4%その他 23.4%

分野

  • Medicine81.4%
  • Biochemistry, Genetics and Molecular Biology12.9%
  • Immunology and Microbiology2.3%
  • Engineering0.6%
  • Computer Science0.5%
  • Chemistry0.5%
  • その他1.8%

トピック

  • Lung Cancer Treatments and Mutations17.8%
  • Cancer Immunotherapy and Biomarkers12.1%
  • Lung Cancer Research Studies9.1%
  • Lung Cancer Diagnosis and Treatment7.8%
  • Cancer Genomics and Diagnostics4%
  • Colorectal Cancer Treatments and Studies2.3%
  • その他46.9%

共著者

全論文

検索で開く
  1. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2016 被引用: 4,780

  2. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2020 被引用: 1,691

  3. Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2020 被引用: 1,756

  4. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

    著者: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 612

  5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Javier Valdivia, Dolores Isla, Manuel Dómine, Olivier Molinier, Julien Mazières, Nathalie Baize, Rosario García‐Campelo, G. Robinet, Delvys Rodríguez‐Abreu, Guillermo López-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, P. Bombaron, Reyes Bernabé, Alessandra Bearz, Á. Artal, Enrico Cortesi, Christian Rolfo, María Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, José Luis Ramírez, José Javier Sánchez, Miguel Ángel Molina‐Vila, Miquel Tarón, Luis Paz‐Ares - The Lancet Oncology 2012 被引用: 5,530

  6. First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer

    著者: , , , , , , , , , , , , , - New England Journal of Medicine 2020 被引用: 1,064

  7. Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mikhail Akimov, Rebecca S. Heist - New England Journal of Medicine 2020 被引用: 997

  8. Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniil Stroyakovskiy, Marina Peregudova, Mehmet Alı Nahıt Şendur, Ozan Yazıcı, Raffaele Califano, Vanesa Gutiérrez Calderón, Filippo de Marinis, Antonio Passaro, Sang‐We Kim, Shirish M. Gadgeel, John Xie, Tao Sun, Melissa Martínez, Mariah Ennis, E. Fennema, Mahesh Daksh, Dawn Millington, Isabelle Leconte, Ryota Iwasawa, Patricia Lorenzini, Mahadi Baig, Sujay Shah, Joshua Bauml, S. Martin Shreeve, Seema Sethi, R.E. Knoblauch, Hidetoshi Hayashi - New England Journal of Medicine 2024 被引用: 375

  9. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 389

  10. Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 被引用: 382

  11. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

    著者: , , , , , , , , , , , , , , , , , - The Lancet Respiratory Medicine 2022 被引用: 221

  12. Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2024 被引用: 313

  13. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis

    著者: , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2019 被引用: 282

  14. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

    著者: , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2021 被引用: 202

  15. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gustavo Werutsky, Sérgio Jobim Azevedo, Fábio Franke, Joilda Batista De Almeida Rego, Pedro Rafael Martins De Marchi, Gustavo Dix Junqueira, Fernanda Maris Peria, Leandro Brust, Parneet Cheema, Mark Doherty, Ambika Parmar, Ines B. Menjak, Natasha B. Leighl, Jason Agulnik, Shun Lü, Zhigang Han, Jiuwei Cui, Li Zhang, Ying Cheng, Gongyan Chen, Helong Zhang, Yu Yao, Chengping Hu, Qiming Wang, Xin Zhang, Yong Zhang, Jianying Zhou, Kejing Ying, Yun Fan, Yan Wang, Ziping Wang, Ji‐Feng Feng, Yingying Du, Lin Wu, Cheng Zhi Huang, Xiangdong Zhou, M. Pérol, Julien Dômont, Corinne Lamour, Julien Dutilh, Youssef Oulkhouir, Virginie Westeel, D. Carmier, Bruno Coudert, Aurélie Lagrange, Dominique Spaëth, Stanislas Ropert, Daniel C. Christoph, Jens Kern, Hans‐Georg Kopp, Frank Griesinger, Rainer Wiewrodt, Martin Wermke, Claas Wesseler, Annette Mueller, G Vogel, Victor Lee, Chung Man James Ho, Siu Hong Oscar Chan, Sing Hung Lo, Shi Feng Jonathan Nyaw, Yu Chung Jacky Li, Jair Bar, Maya Gottfried, Julia Dudnik, Alona Zer, Mor Moskovitz, Mirjana Wollner, Ofer Rotem, Sivan Shamai ほか 111 名 - Journal of Clinical Oncology 2024 被引用: 142

  16. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jian Fang, Wei Li, Jianying Zhou, Jun Zhao, Ying Cheng, Chih-Hsin Yang, Gee‐Chen Chang, Yuh‐Min Chen, Te‐Chun Hsia, Chih‐Feng Chian, Cheng-Ta Yang, Chin‐Chou Wang, Sang‐We Kim, Keunchil Park, Dong‐Wan Kim, Byoung Chul Cho, Ki Hyeong Lee, Young‐Chul Kim, Ho Jung An, In Sook Woo, Y. Choi, Sang Won Shin, Jong Seok Lee, Joo-Hang Kim, Seung Soo Yoo, Terufumi Kato, Naofumi Shinagawa, Ross A. Soo, Shao Weng Daniel Tan, Lynette Si-Mien Ngo, Kananathan Ratnavelu, Azura Rozila Ahmad, Chong Kin Liam, Filippo de Marinis, Pierfrancesco Tassone, Amelia Insa Molla, Antonio Calles, Martín Emilio Lázaro Quintela, Enriqueta Felip Font, Anne‐Marie C. Dingemans, Lynne A. Bui - The Lancet Respiratory Medicine 2020 被引用: 258

  17. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 94

  18. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel Brungs, Bo Gao, Adnan Nagria, Christos S. Karapetis, Sagun Parakh, Cheol Park, Gaëtan Catala, Frédéric Forget, Sebahat Ocak, Naveen S. Basappa, Geoffrey Liu, Ines B. Menjak, Benjamin Shieh, Shun Lü, Feng Luo, Hongmei Sun, Jialei Wang, Yu Yao, Milada Zemanová, Jaafar Bennouna, Nicolas Girard, Laurent Greillier, Corinne Lamour, H. Léna, Céline Mascaux, Julien Mazières, Denis Moro‐Sibilot, M. Pérol, Elvire Pons‐Tostivint, Virginie Westeel, Akin Atmaca, Christine Greil, Niels Reinmuth, Christian Schumann, Thomas Wehler, Juergen Wolf, James Ho, Csaba Böcskei, Federico Cappuzzo, Filippo de Marinis, Claudia Proto, Manlio Mencoboni, Silvia Novello, Stefania Salvagni, Héctor Soto Parrà, Haruko Daga, Yasushi Goto, Hidetoshi Hayashi, Satoru Kitazono, Kiyotaka Yoh, Ryo Ko, Masashi Kondo, Toshiyuki Kozuki, Takayasu Kurata, Hideaki Mizutani, Kadoaki Ohashi, Satoshi Oizumi, Isamu Okamoto, Satoshi Sakaguchi, H Ozasa, Shunichi Sugawara, Yuichi Tambo, Motohiro Tamiya, Hiroshi Tanaka, Isamu Okamoto, Froylán López-López, Francisco Javier Ramírez Godinez, Jerónimo Rafael Rodríguez Cid, Robin Cornelissen, Steven Gans ほか 61 名 - Journal of Clinical Oncology 2024 被引用: 182

  19. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2008 被引用: 3,221

  20. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

    著者: , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2019 被引用: 491

  21. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wim Demey, Paul Germonpré, Elke Govaerts, Thierry Pieters, Reinier Wener, Alan A. Azambuja, Giuliano Santos Borges, Gilberto de Castro, Suellen Castro, Felipe Melo Cruz, Fábio Franke, Eduardo Silva, Parneet Cheema, Robert H. El-Maraghi, Swati Kulkarni, Rami Nassabein, Scott Owen, Clarisse Audigier-Valette, Jaafar Bennouna, C. Chouaïd, Alexis B. Cortot, S. Couraud, D. Debieuvre, Fabrice Denis, Patrick Dumont, Radj Gervais, Nicolas Girard, Etienne Giroux‐Leprieur, Florian Guisier, Sandrine Hiret, Henri Janicot, Corinne Lamour, J. Madelaine, M. Marcq, E. Pluquet, Jean Louis Pujol, Magali Ravoire, Marielle Sabatini, A. Vergnenègre, Sabine Bohnet, Martin Faehling, Melanie Janning, Eckart Laack, Niels Reinmuth, Achim Rittmeyer, Claas Wesseler, Sofia Baka, George Fountzilas, Panagiotis Katsaounis, Αthanasios Kotsakis, Ioannis Mountzios, Konstantinos Syrigos, Julia Dudnik, Fink Carmel, Ofer Merimsky, Hovav Nechushtan, Julia Sobolev, Franceso Agustoni, Anna Bettini, Matteo Brighenti, Giulio Cerea, Filippo de Marinis, Salvatore Grisanti, Francesco Grossi, Andrea Luciani, Evaristo Maiello, Héctor Soto Parrà, Pierfrancesco Tassone, Giuseppe Tonini, Yoko Agemi ほか 101 名 - Journal of Clinical Oncology 2024 被引用: 115

  22. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sabine Bohnet, Ekaterini Boleti, Hossein Borghaei, Penelope A. Bradbury, Matteo Brighenti, Nicholas Campbell, Toby Campbell, Jean-Luc Canon, Federico Cappuzzo, Enric Carcereny Costa, Luigi Cavanna, Jeremy Cetnar, Antonio Chella, C. Chouaïd, Daniel C. Christoph, J. Cortés Castán, Shaker R. Dakhil, F.J. de Castro Carpeño, Filippo de Marinis, Angelo Delmonte, Ingel Demedts, Wim Demey, Joyce Dits, Maria del Pilar Diz Taín, M. Dómine Gómez, Timothy Dorius, Daphne W. Dumoulin, M. Duruisseaux, Keith D. Eaton, Emilio Esteban González, Devon Evans, Martin Faehling, Nicholas Farrell, Trevor Feinstein, E. Felip Font, M.R. García Campelo, Edward B. Garon, María Pilar Garrido López, Paul Germonpré, Todd Gersten, María González Cao, Srivalli Gopaluni, Laurent Greillier, Francesco Grossi, Florian Guisier, Sarada Gurubhagavatula, Vanesa Gutiérrez Calderón, David Hakimian, Richard D. Hall, Desirée Hao, Ronald Harris, Sayed M.S. Hashemi, Kai He, Lizza Hendriks, Chao Huang, Emad Ibrahim, Sharad Jain, Melissa L. Johnson, B. J. P. Jones, Monte Jones, Óscar Juan, Rosalyn A. Juergens, Courèche Kaderbhaï, Elisabeth A. Kastelijn, Roger Keresztes, Ebenezer A. Kio, Konrad Kokowski, Kartik Konduri, Swati Kulkarni, Jonas Kuon ほか 84 名 - Annals of Oncology 2023 被引用: 93

  23. LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 71

  24. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James Chih‐Hsin Yang, Yasushi Yatabe, George Pentheroudakis, Solange Peters - Annals of Oncology 2022 被引用: 190